one8zero8 LLC Invests $3.51 Million in Revvity, Inc. (NYSE:RVTY)

one8zero8 LLC acquired a new position in Revvity, Inc. (NYSE:RVTY) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 31,456 shares of the company’s stock, valued at approximately $3,511,000.

A number of other hedge funds have also recently made changes to their positions in the business. Victory Capital Management Inc. boosted its stake in Revvity by 17.4% during the fourth quarter. Victory Capital Management Inc. now owns 70,250 shares of the company’s stock valued at $7,841,000 after buying an additional 10,390 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Revvity by 13.7% during the third quarter. JPMorgan Chase & Co. now owns 344,115 shares of the company’s stock valued at $43,961,000 after buying an additional 41,497 shares during the last quarter. Contravisory Investment Management Inc. boosted its stake in Revvity by 1,715.9% during the fourth quarter. Contravisory Investment Management Inc. now owns 69,186 shares of the company’s stock valued at $7,722,000 after buying an additional 65,376 shares during the last quarter. FMR LLC boosted its stake in Revvity by 40.8% during the third quarter. FMR LLC now owns 155,556 shares of the company’s stock valued at $19,872,000 after buying an additional 45,040 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its stake in Revvity by 87.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 7,891 shares of the company’s stock valued at $881,000 after buying an additional 3,672 shares during the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Trading Up 1.6 %

Shares of NYSE RVTY opened at $112.13 on Friday. The business’s 50 day moving average price is $117.01 and its 200-day moving average price is $117.95. The company has a market cap of $13.47 billion, a price-to-earnings ratio of 50.74, a PEG ratio of 3.82 and a beta of 1.06. Revvity, Inc. has a fifty-two week low of $97.32 and a fifty-two week high of $129.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Friday, January 31st. The company reported $1.42 EPS for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the prior year, the company posted $1.25 EPS. On average, sell-side analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be issued a dividend of $0.07 per share. The ex-dividend date is Thursday, April 17th. This represents a $0.28 annualized dividend and a yield of 0.25%. Revvity’s payout ratio is currently 12.67%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. KeyCorp raised their price objective on Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Sanford C. Bernstein lowered Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price objective for the company. in a research note on Friday, January 10th. Bank of America raised Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price objective for the company in a research note on Friday, December 13th. Barclays raised their price objective on Revvity from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, Raymond James reaffirmed an “outperform” rating and issued a $145.00 price objective (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $136.25.

Insiders Place Their Bets

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the sale, the insider now owns 33,400 shares of the company’s stock, valued at approximately $4,232,782. This trade represents a 31.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tajinder S. Vohra sold 5,492 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the sale, the insider now directly owns 19,652 shares in the company, valued at $2,295,550.12. This trade represents a 21.84 % decrease in their position. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by company insiders.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.